2024 年业绩符合我们预期公司公布2024 年业绩:收入9.81 亿元,同比+342%;归母净利润亏损4.06 亿元,2024 年业绩符合我们预期。发展趋势2024 年奥雷巴替尼国内稳健放量,开启全球开发。2024 年,奥雷巴替尼中国销售收入2.41 亿元,同比增长52%,2024 年11 月奥雷巴替尼新适应症对一代和二代TKI 耐药和/或不耐受的CML-CP 进入国家医保目录,我们预计有望驱动...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.